Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Abstract Text:

BackgroundDespite the frequent simultaneous presentation of cardiac and renal dysfunction, the relationship between these pathophysiological processes remains unclear. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase, which has been linked to endothelial dysfunction and atherosclerosis. This study elucidates the relationship between ADMA and intrarenal and coronary microvascular diseases.MethodsIn this study, we included 66 consecutive hypertensive patients with normal renal function or mild renal insufficiency (creatinine /=90 ml/min; renal insufficiency group, eGFR <90 ml/min). Coronary flow velocity reserve (CFVR) was measured using adenosine-triphosphate stress transthoracic Doppler echocardiography. In addition, a plasma ADMA assay, echocardiography, carotid ultrasound, and brachial-ankle pulse wave velocity measurement were performed.ResultsThe plasma ADMA level was the highest in patients with both renal insufficiency and reduced CFVR. ADMA was significantly associated with eGFR (r = -0.342, P = 0.006) and CFVR (r = -0.459, P < 0.001), and eGFR and CFVR were significantly associated with each other (r = 0.337, P = 0.006). Multiple regression analysis revealed that ADMA was an independent clinical parameter associated with both eGFR and CFVR.ConclusionsPlasma ADMA is suggested to be an incipient biochemical marker of microvascular disease in both kidney and heart in hypertensive patients. ADMA might play an important role in the pathogenesis of organ damage in the kidney and heart in essential hypertension.American Journal of Hypertension doi:10.1038/ajh.2008.29American Journal of Hypertension (2008); 21, 6, 650-656. doi:10.1038/ajh.2008.29.

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of hypertension : journal of the

VOLUME: 21

Page Numbers: 650-6

Journal Abbreviation: Am. J. Hypertens.

ISSN: 0895-7061

DAY: 20

MONTH: 03

YEAR: 2008

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8803676

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.

AFFILIATION: [1] 1Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan [2] 2Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Hypertens

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients Related Publications

• A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
• Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells.
• Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
• Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats.
• CENP-O Class Proteins Form a Stable Complex and Are Required for Proper Kinetochore Function.
• Down-regulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats.
• Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells.
• Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress.
• Protein and energy interactions throughout life. Metabolic basis and nutritional implications.
• Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.
• Putative role of endothelial lipase in dialysis patients with hypoalbuminemia and inflammation.
• Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients.
• Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient.
• The kinetochore and spindle checkpoint in vertebrate cells.
• Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
• Whole or fragmentary information on parathyroid hormone?
• [Basic and Clinical Aspects of Calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation.]
• [Basic and Clinical Aspects of Calcimimetics. Cinacalcet, effect and mechanisms of action.]
• [Basic and Clinical Aspects of Calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics.]
• [The metabolic syndrome and bone health. The Relationship Between Lipid and Glucose Metabolism and Bone Mineral Metabolism : Pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia.]